Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What they need to stengthen their negotiating position for a TO:
1. Good Activ-2 data.
2. Good Long Covid data.
3. Inclusion on one or more clinical trials.
If this happens, we will be TO by a larger pharma.
if that lot turned up on Dragons den they would probably say they had a good business idea, but when questioned about the business bringing to market I think they would be escorted to the door.
Funny enough they do need help J/V or buyout is the quickest route for every one concerned there not getting any younger
Wigster….Was excited about the Twinnings… Maude is now using the tea bags twice after which she hangs them out to dry… a little like us all here. I really do hope…actually pray now that Poly get involved. 70% survival rate in the seriously ill and we get… we are looking at hopefully convincing someone, somewhere, anywhere to let us have a trial. I am not a scientist but this lot are definitely not business people…. AGM for me. Hopefully see some of you there!!!!!
just bought £10 K in my Sipp @ £25.39 this defiantly my last buy
Nail on the head there Aether
Agreed. I can't see why there are clearly some very disappointed investors who are selling out. There was nothing particularly surprising in the presentation, and there is plenty of grounds for hope that some good news could emerge soon, most likely inclusion on a big trial. The share price seems low, and is now the same as before the announcement of the 70% reduction in death for the sub-groups. Doesn't seem logical.
Perhaps there is only so much the BoD can do without the Activ-2 and Long Covid data.
The ATS presentation of the DD data was good. (The DD data was good and the Activ-2 data will probably be good.)
The mood music from the WH, WHO, NIH, and Gates Foundation about the need for inhaled interferons is good.
I wasn't expecting much else from this update.
So, we need:
1. Good Activ-2 data. This is being released soon.
2. Inclusion on a clinical trial. This is under discussion and the NIH is rewriting our protocol.
Only inclusion on a clinical trial, a TO, JV, or EUA will shift the share price to a new trading range.
"It was down 15% when I went out a hour ago now down 27% did I liss anything"
The new cheaper tea-bags that Maude negotiated a fantastic price on are actually out of date and taste like crap.
It was down 15% when I went out a hour ago now down 27% did I liss anything
WE need someone to step in, these people might be good scientists but they are terrible business men.
WE need quick TR1 from Poly to say they are taking private and paying one pound a share....feck it I will sell my 60K shares
Oh well if it goes well in to 2023 so be it . Will just put in the bottom drawer.
Me too, £5k at 25.06!!
I reckon you be right there Tommy....
Sp movement over the past couple of days a joke.... mms having a field day lol
I didn't get to see the presentation.
Fundamentally the drug needs another trial. This was true immediately after the Sprinter results and with just 110 Activ 2 patients dosed, even if that data is very good, it cannot proceed to market.
I have kept my SNG shares and for the long haul I suppose. We could get a takeover and that would suit me as it provides closure and perhaps a small profit. Good luck all.
Looks like an MM scalpinng trip to me....took the opportunity to add another 5k
Synairgen are about as authentic as a Milli Vanilli concert .
It's like musical chairs nowadays. Not many want to hold a share for very long. I would imagine some are taking losses at the moment.
Silly really as there is the potential here. It could rebound after the losses have been done with.
Hope they hurry up and get off the stage the price just keeps on tanking.
Strange one not knowing when the next big RNS is due. All down to RM and team getting on a platform trial or awaiting details of a JV. Activ2 data - I think he said 'we will receive some on the data during the summer'.
No mention of long covid data and no mention of next trials with Activ.
Interesting to learn they are due a cheque in second half of the year from HMRC for £9.2M for R&D tax credit so no issue with cash for the medium term.
Nothing we can do but wait.
Upbeat but didn’t get any impression of commercialisation likely in 2022. Looks like we are in this long haul into 2023.
He finished off by saying they were in talks with the multiplatform trials , but also with Industry regarding partnering , using the data that they have from all trials and lab studies . Well financed and in a good position for these talks .
Did I hear correctly from RM about looking for Industry partners to progress the drug right towards the end of the presentation? That is encouraging if so.
has it finished
Slide shows 110 patients on both drug and placebo with Activ2 - and says that they were excited enough with the data to progress it to P3 ( although now paused) .
Yet to see results - coming this summer .
He is in good form - running through Sprinter now .
Interesting stats he is highlighting .